Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Immucor -- Ignore unavailable to you. Want to Upgrade?

To: Mason Barge who wrote (297)	3/15/1999 4:00:00 PM
From: Sidney Merle Foster	Read Replies (2) \| Respond to of 422

Am I missing something? Every time Immucor announces good news the stock drops. Could someone, perhaps a more experienced investor than myself, explain what is taking place and what maybe could be done to have the stock respond in the ways of most other stocks. Sid

To: Mason Barge who wrote (297)	4/6/1999 9:24:00 PM
From: Thomas Kirwin	Respond to of 422

Immucor, Inc. Signs Definitive Agreement to Acquire Biopool's Blood Bank Division Tuesday April 6, 9:01 am Eastern Time Company Press Release NORCROSS, Ga., April 6 /PRNewswire/ -- Immucor, Inc. (Nasdaq: BLUD - news), a leading provider of blood bank reagents and related products, today announced the signing of a definitive agreement for the purchase of certain assets of the BCA blood bank division of Biopool International Inc. (Nasdaq: BIPL - news). The acquired product lines currently generate approximately $5.5 million in annual revenues, and are expected to be immediately accretive to Immucor's earnings per share. The purchase price is $3.0 million for net working capital plus $1.5 million for the product lines. The transaction is expected to close on May 1, 1999. Under the terms of the agreement, Biopool will continue to operate the BCA facility on behalf of Immucor during a transition period. Commenting on this transaction Edward L. Gallup, President of Immucor, stated, ''As evidenced by our recent acquisitions of Dominion Biologicals Ltd., Gamma Biologicals and Immunochim/Medichim, our French/Belgian distributor, we are implementing our strategy of market consolidation and the establishment of a direct presence in the more important global markets.'' Gallup further stated, ''The purchase of BCA continues our consolidation of the U. S. market as Immucor will now stand as one of only two major players with a complete line of blood bank reagents. Immucor is the market leader in automated instruments and reagents. We believe we are the number one supplier for our field in the North American market and expect this position to strengthen in the future.'' Immucor manufactures and sells a complete line of reagents and systems used by hospitals, reference laboratories and donor centers to detect and identify certain properties of the cell and serum components of blood prior to transfusion. Founded in 1982, Immucor markets a complete family of automated instrumentation for all of our market segments. For more information on Immucor, please visit the company's website at immucor.com . This press release may contain forward-looking statements as that term is defined in the Private Securities Reform Act of 1995, including, without limitation, statements concerning the Company's expectations, beliefs, intentions or strategies regarding the future. All forward-looking statements included in this document are based on information available to the Company on the date hereof, and the Company assumes no obligation to update any such forward-looking statements. There is no certainty that the acquired product lines will continue to generate revenues at the same level in the future. Further risks are detailed in the Company's filings with the Securities and Exchange Commission, including those set forth in the Company's most recent Form 10-K and Quarterly Reports on Form 10-Q. SOURCE: Immucor, Inc.